Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
05 2019
Historique:
received: 04 11 2018
revised: 27 02 2019
accepted: 05 03 2019
pubmed: 2 4 2019
medline: 1 7 2020
entrez: 2 4 2019
Statut: ppublish

Résumé

The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large-scale Asian studies that include follow-up data have been reported. To investigate the clinical characteristics of Japanese patients with melanoma and to evaluate the prognostic factors. Detailed patient information was collected from the database of Japanese Melanoma Study Group of the Japanese Skin Cancer Society. The American Joint Committee on Cancer seventh Edition system was used for TNM classification. The Kaplan-Meier method and Cox proportional hazards model were used to estimate the impact of clinical and histological parameters on disease-specific survival in patients with invasive melanoma. In total, 4594 patients were included in this analysis. The most common clinical type was acral lentiginous melanoma (40.4%) followed by superficial spreading melanoma (20.5%), nodular melanoma (10.0%), mucosal melanoma (9.5%), and lentigo maligna melanoma (8.1%). The 5-year disease-specific survival for each stage was as follows: IA = 98.0%, IB = 93.9%, IIA = 94.8%, IIB = 82.4%, IIC = 71.8%, IIIA = 75.0%, IIIB = 61.3%, IIIC = 41.7%, and IV = 17.7%. Although multivariate analysis showed that clinical classifications were not associated with survival across all stages, acral type was an independent poor prognostic factor in stage IIIA. Our study revealed the characteristics of melanoma in the Japanese population. The 5-year disease-specific survival of each stage showed a similar trend to that of Caucasians. While clinical classification was not associated with survival in any stages, acral type was associated with poor survival in stage IIIA. Our result might indicate the aggressiveness of acral type in certain populations.

Sections du résumé

BACKGROUND
The incidence of melanoma among those of an Asian ethnicity is lower than in Caucasians; few large-scale Asian studies that include follow-up data have been reported.
OBJECTIVES
To investigate the clinical characteristics of Japanese patients with melanoma and to evaluate the prognostic factors.
METHODS
Detailed patient information was collected from the database of Japanese Melanoma Study Group of the Japanese Skin Cancer Society. The American Joint Committee on Cancer seventh Edition system was used for TNM classification. The Kaplan-Meier method and Cox proportional hazards model were used to estimate the impact of clinical and histological parameters on disease-specific survival in patients with invasive melanoma.
RESULTS
In total, 4594 patients were included in this analysis. The most common clinical type was acral lentiginous melanoma (40.4%) followed by superficial spreading melanoma (20.5%), nodular melanoma (10.0%), mucosal melanoma (9.5%), and lentigo maligna melanoma (8.1%). The 5-year disease-specific survival for each stage was as follows: IA = 98.0%, IB = 93.9%, IIA = 94.8%, IIB = 82.4%, IIC = 71.8%, IIIA = 75.0%, IIIB = 61.3%, IIIC = 41.7%, and IV = 17.7%. Although multivariate analysis showed that clinical classifications were not associated with survival across all stages, acral type was an independent poor prognostic factor in stage IIIA.
CONCLUSIONS
Our study revealed the characteristics of melanoma in the Japanese population. The 5-year disease-specific survival of each stage showed a similar trend to that of Caucasians. While clinical classification was not associated with survival in any stages, acral type was associated with poor survival in stage IIIA. Our result might indicate the aggressiveness of acral type in certain populations.

Identifiants

pubmed: 30932370
doi: 10.1002/cam4.2110
pmc: PMC6536943
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2146-2156

Informations de copyright

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Br J Dermatol. 2018 Feb;178(2):443-451
pubmed: 28707317
Nat Rev Clin Oncol. 2010 Jan;7(1):60-3
pubmed: 20029445
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Invest New Drugs. 2016 Dec;34(6):677-684
pubmed: 27491654
N Engl J Med. 2005 Nov 17;353(20):2135-47
pubmed: 16291983
Cancer Med. 2019 May;8(5):2146-2156
pubmed: 30932370
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Br J Dermatol. 2000 Aug;143(2):275-80
pubmed: 10951133
J Dermatol Sci. 2018 Jan;89(1):60-66
pubmed: 29079332
Eur J Cancer. 2017 Apr;75:47-55
pubmed: 28214657
J Dermatol. 2018 Nov;45(11):1337-1339
pubmed: 30204266
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Am J Dermatopathol. 1984 Summer;6 Suppl:43-53
pubmed: 6528942
Br J Cancer. 2016 May 10;114(10):1084-9
pubmed: 27124339
Pigment Cell Melanoma Res. 2011 Apr;24(2):345-51
pubmed: 21324100
Melanoma Res. 2017 Oct;27(5):492-497
pubmed: 28609317
BMC Cancer. 2016 Aug 30;16:691
pubmed: 27576582
Adv Anat Pathol. 2000 May;7(3):167-80
pubmed: 10809223
Oncologist. 2016 Jul;21(7):848-54
pubmed: 27286787
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):438-442
pubmed: 27518480
Cancer Sci. 2017 Jun;108(6):1223-1230
pubmed: 28342215
Int J Dermatol. 2018 Jan;57(1):21-27
pubmed: 29231241
Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8
pubmed: 24913711
Int J Clin Oncol. 2008 Feb;13(1):33-41
pubmed: 18307017
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Chemother Pharmacol. 2017 Apr;79(4):651-660
pubmed: 28283736
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Int J Clin Oncol. 2001 Jun;6(3):109-16
pubmed: 11706778
J Dermatol Sci. 2015 Oct;80(1):33-7
pubmed: 26282084

Auteurs

Yasuhiro Fujisawa (Y)

Japanese Melanoma Study Group, Tsukuba, Japan.
Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Kumamoto, Japan.
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.

Shusuke Yoshikawa (S)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.

Akane Minagawa (A)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.

Tatsuya Takenouchi (T)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Niigata Cancer Center, Niigata, Japan.

Kenji Yokota (K)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, University of Nagoya, Nagoya, Japan.

Hiroshi Uchi (H)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, University of Kyushu, Fukuoka, Japan.

Naoki Noma (N)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Osaka City University, Osaka, Japan.

Yasuhiro Nakamura (Y)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Saitama Medical University International Medical Center, Hidaka, Japan.

Jun Asai (J)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Junji Kato (J)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Sapporo Medical University, Sapporo, Japan.

Susumu Fujiwara (S)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Kobe University, Kobe, Japan.

Satoshi Fukushima (S)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan.

Jiro Uehara (J)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan.

Toshihiko Hoashi (T)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Nippon Medical School, Bunkyo-ku, Japan.

Tatsuya Kaji (T)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Okayama University Graduate School of Medicine, Okayama, Japan.

Taku Fujimura (T)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Kenjiro Namikawa (K)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Manabu Yoshioka (M)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, University of Occupational and Environment Health, Kitakyushu, Japan.

Naoki Murao (N)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Plastic Surgery, University of Hokkaido, Sapporo, Japan.

Dai Ogata (D)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Saitama Medical University, Hidaka, Japan.

Kanako Matsuyama (K)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, University of Gifu, Gifu, Japan.

Naohito Hatta (N)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Toyama Prefectural Central Hospital, Toyama, Japan.

Yoshitsugu Shibayama (Y)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Fukuoka University, Fukuoka, Japan.

Toshiharu Fujiyama (T)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Masashi Ishikawa (M)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Saitama Prefectural Cancer Center, Saitama, Japan.

Daisuke Yamada (D)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, University of Tokyo, Tokyo, Japan.

Akiko Kishi (A)

Japanese Melanoma Study Group, Tsukuba, Japan.
Department of Dermatology, Toranomon Hospital, Minato-ku, Japan.

Yoshiyuki Nakamura (Y)

Department of Dermatology, University of Tsukuba, Tsukuba, Japan.

Takatoshi Shimiauchi (T)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Kumamoto, Japan.
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Kazuyasu Fujii (K)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Kumamoto, Japan.
Department of Dermatology, Kagoshima University, Kagoshima, Japan.

Manabu Fujimoto (M)

Department of Dermatology, University of Tsukuba, Tsukuba, Japan.

Hironobu Ihn (H)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Kumamoto, Japan.
Department of Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan.

Norito Katoh (N)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Kumamoto, Japan.
Department of Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH